Paper Details

  1. Home
  2. Paper Details

Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.

Author: BoldKrysten W, FucitoLisa M, GueorguievaRalitza, JatlowPeter, MuvvalaSrinivas, O'MalleyStephanie S, OckertDavid M, PetrakisIsmene, PiepmeierMary E, WuRan, ZwebenAllen

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that varenicline with medical management resulted in decreased heavy drinking among men and increased smoking abstinence in the overall sample.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Individuals with alcohol use disorder have high rates of cigarette smoking. Varenicline tartrate, an approved treatment for smoking cessation, may reduce both drinking and smoking. OBJECTIVES: To test the efficacy of varenicline with medical management for patients with alcohol use diso...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838706/

データ提供：米国国立医学図書館（NLM）

Combating Dual Addictions: Varenicline's Role in Alcohol and Nicotine Dependence

Alcohol and nicotine dependence are significant health challenges that often coexist. This study explores the potential of varenicline, a medication used to aid smoking cessation, in treating alcohol use disorder and comorbid smoking. It investigates whether varenicline can effectively reduce both drinking and smoking, offering hope for individuals struggling with these dual addictions. It's like navigating a desert landscape, searching for a single oasis that can provide relief from both thirst and hunger.

Varenicline's Potential: A Double-Edged Sword

The study investigated the efficacy of varenicline in treating alcohol use disorder and comorbid smoking. The researchers found that varenicline with medical management led to decreased heavy drinking among men and increased smoking abstinence in the overall sample. This research is like discovering a hidden spring in the desert, a source of potential benefit for individuals struggling with both alcohol and nicotine dependence, but the results suggest that varenicline's effects may vary depending on the individual.

A New Frontier: Treating Dual Addictions

The study's findings highlight the need for further research into effective treatments for dual addictions. It's like exploring a vast desert, seeking to understand the complex interplay of different addictions and find ways to address them effectively. While varenicline showed promise in this study, further research is needed to optimize its use and explore other potential interventions for those struggling with these intertwined challenges.

Dr.Camel's Conclusion

This research explores the potential of varenicline in treating alcohol use disorder and comorbid smoking. It's like discovering a new oasis in the desert, offering hope for individuals battling these dual addictions. While the study suggests that varenicline may be effective in some cases, further research is needed to fully understand its potential and develop more comprehensive treatment strategies for these complex conditions.

Date :
  1. Date Completed 2019-09-11
  2. Date Revised 2019-09-11
Further Info :

Pubmed ID

29261824

DOI: Digital Object Identifier

PMC5838706

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.